Method of determining the presence of endotoxin in a sample

• US 5,591,628 A
• Filed: 05/28/1990
• Issued: 01/07/1997
• Est. Priority Date: 05/20/1987
• Status: Expired due to Fees

• Current Assignee: B.Ae Butted.K, Leif, Claus Koch
• Original Assignee: B.Ae Butted.K, Leif, Claus Koch
• Inventors: Koch, Claus, B.ae butted.k, Leif
• Primary Examiner(s): Nucker, Christine M.
• Assistant Examiner(s): STUCKER, JEFFREY J
• Application Number:
  US08/068,178
• Time in Patent Office: 2,416 Days
• Field of Search: 436/548, 530/387.1, 530/388.26, 530/388.1, 530/389.1, 435/7.21, 435/7.9, 435/7.4, 435/7.32, 435/7.5, 435/8, 435/12, 435/23, 435/27, 435/28, 435/188, 435/7.1, 435/7.92, 435/7.8, 435/240.1, 435/240.26, 435/240.27
• US Class Current: 435/70.21
• CPC Class Codes: G01N 33/56916 Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
• CPC Class Codes: G01N 33/579 involving limulus lysate

Abstract

There is disclosed a method for determining the presence of endotoxin or an endotoxin like substance in a sample, as well as a monoclonal antibody and test kit useful in the method.

Claims

1. A monoclonal antibody which specifically binds to coagulogen of a limulus amoebocyte lysate, but does not bind to coagulogen of said limulus amoebocyte lysate which has been contacted with activated clotting enzyme of said limulus amoebocyte lysate.

8. A test kit for determining the presence of a compound that initiates a limulus amoebocyte lysate clotting cascade, in a sample, comprising at least one monoclonal antibody according to claim 1 or 2 and a container.

9. A test kit according to claim 8, wherein said at least one monoclonal antibody includes a monoclonal antibody that specifically binds to C-peptide.

10. A test kit according to claim 8, which comprises two or more monoclonal antibodies.

11. A test kit according to claim 8, wherein said at least one monoclonal antibody is covalently labeled.

12. A test kit according to claim 11, wherein said label is selected from the group consisting of an enzyme, a fluorescent substance, a chemiluminescent substance, a chromophore, a radioactive isotope and a complexing agent.

13. A test kit according to claim 12, wherein said label is an enzyme selected from the group consisting of a peroxidase, a phosphatase, β

-galactosidase, urease, glucose oxidase, carbonic anhydrase, acetylcholinesterase, glucoamylasae, lysozyme, malate dehydrogenase, glucose-6-phosphate dehydrogenase and ribonuclease.

14. A test kit according to claim 13, which further comprises a substrate for said enzyme, wherein said substrate is selected from the group consisting of a chromogenic substrate, a substrate forming a fluorescent product and a substrate forming a chemiluminescent product.

15. A test kit according to claim 12, wherein said fluorescent substance is selected from the group consisting of 4-methylumbelliferyl phosphate, 4-methylumbelliferyl-D-galactopyranoside and 3-(p-hydroxphenyl)-propionic acid.

16. A test kit according to claim 14, wherein said enzyme and substrate are together peroxidase and eosin or luciferase and a substrate for luciferase.

17. A test kit according to claim 12, wherein said label is isoluminol.

18. A test kit according to claim 12, wherein said label is a radioactive substance selected from the group consisting of ¹²⁵ I, ³ H, ³⁵ P, ¹³¹ I and ¹⁴ C.

19. A test kit according to claim 12, wherein said label is a complexing agent selected from the group consisting of biotin, Protein A and a lectin.

20. A test kit according to claim 8, which further comprises a solid support.

21. A test kit according to claim 20, wherein said solid support is selected from the group consisting of a plastic, nitrocellulose, cyanogen-bromide activated paper, 1-3(nitrobenzyloxymethyl)pyridium chloride activated paper, diazobenzyloxymethyl paper, nitrobenzylmethyl paper, aminobenzyloxymethyl paper, a silicone polymer and a silicate.

22. A test kit according to claim 8, which comprises both a labeled antibody and an unlabeled antibody.

23. A test kit according to claim 8, which further comprises an endotoxin standard.

24. A test kit according to claim 8, which further comprises pyrogen-free water.

25. A test kit according to claim 8, which further comprises a limulus amoebocyte lysate or hemolymph.

2. A monoclonal antibody which specifically binds to a product of a coagulogen of a limulus amoebocyte lysate wherein said product is formed upon contact of aid coagulogen with activated clotting enzyme of said limulus amoebocyte lysate, but which does not bind to said coagulogen that has not been contacted with activated clotting enzyme of said limulus amoebocyte lysate.

5. A monoclonal antibody according to claim 2, which specifically binds to C-peptide.

6. A monoclonal antibody according to claim 2, which specifically binds to non-covalently cross-linked coagulin.

7. A monoclonal antibody according to claim 2, which specifically binds to covalently cross-linked coagulin.

3. A monoclonal antibody produced by a hybridoma isolated by a method comprising:

i) producing a pool of hybridomas secreting monoclonal antibodies by immunizing an animal with coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of aid coagulogen;

ii) testing said pool of hybridomas for secretion of a monoclonal antibody that specifically binds to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen;

iii) testing said pool of hybridomas for secretion of a monoclonal antibody that does not bind to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium; and

iv) isolating those hybridomas which secrete a monoclonal antibody that specifically binds to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen and that does not bind to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium.

4. A monoclonal antibody produced by a hybridoma isolated by a method comprising:

i) producing a pool of hybridomas secreting monoclonal antibodies by immunizing an animal with coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of aid coagulogen;

ii) testing said pool of hybridomas for secretion of a monoclonal antibody that specifically binds to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen;

iii) testing said pool of hybridomas for secretion of a monoclonal antibody that does not bind to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium; and

iv) isolating those hybridomas which secrete a monoclonal antibody that specifically binds to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium and that does not bind to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen.

26. A method for producing a monoclonal antibody which specifically binds to coagulogen of a limulus amoebocyte lysate, but does not bind to coagulogen of said limulus amoebocyte lysate which has been contacted with activated clotting enzyme of said limulus amoebocyte lysate, comprising:

i) producing a pool of hybridomas secreting monoclonal antibodies by immunizing an animal with coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen;

ii) testing said pool of hybridomas for secretion of a monoclonal antibody that specifically binds to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen;

iii) testing said pool of hybridomas for secretion of a monoclonal antibody that does not bind to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium; and

iv) isolating those hybridomas which secrete a monoclonal antibody that specifically binds to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen and that does not bind to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium;

v) culturing a hybridoma obtained from step (iv); and

vi) isolating a monoclonal antibody from the hybridoma culture.

27. A method for isolating a monoclonal antibody which specifically binds to a product of a coagulogen of a limulus amoebocyte lysate wherein said product is formed upon contact of said coagulogen with activated clotting enzyme of said limulus amoebocyte lysate, but which does not bind to said coagulogen that has not ben contacted with activated clotting enzyme of said limulus amoebocyte lysate, comprising:

i) producing a pool of hybridomas secreting monoclonal antibodies by immunizing an animal with said product of a coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen product;

ii) testing said pool of hybridomas for secretion of a monoclonal antibody that specifically binds to said product of a coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen product;

iii) testing said pool of hybridomas for secretion of a monoclonal antibody that does not bind to said coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium; and

iv) isolating those hybridomas which secrete a monoclonal antibody that specifically binds to said product of a coagulogen of a limulus amoebocyte lysate wherein said limulus amoebocyte lysate has been contacted with a lipopolysaccharide of a gram-negative bacterium and that does not bind to said coagulogen of a limulus amoebocyte lysate or with an antigen comprising an immunologic determinant of said coagulogen;

v) culturing a hybridoma obtained from step (iv); and

vi) isolating a monoclonal antibody from the hybridoma culture.